SG3SBIO@EC2602A(19834.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
SG3SBIO@EC2602A
19834.HK
News
View More

Morning Trend | SINO BIOPHARM rebounds from low points, will a rebound window open?

SINO BIOPHARM (1177.HK) has recently experienced a prolonged period of low price fluctuations, with daily candlesticks showing slight alternation between bullish and bearish trends, and an overall downward shift in focus. In the past few trading days, the stock price has retraced to the vicinity of previous low ranges, with trading volume continuously shrinking and market participants showing strong wait-and-see sentiment. From a technical perspective, the MACD indicator remains in a death cross, with significant green bars, indicating a large divergence between bulls and bears in the short term. Fundamentally, the company focuses on its pharmaceutical core business, possessing strong R&D capabilities and product resources. However, it is affected by industry medical insurance cost control, centralized procurement pressures, and a slowdown in sequential performance growth, leading to weakened market confidence. The overall valuation of the Hong Kong pharmaceutical sector is under pressure, with limited inflow momentum from northbound and foreign capital, and a noticeable decline in trading enthusiasm. Meanwhile, the global interest rate hike cycle and the continued weakness of the Hong Kong dollar are also macroeconomic headwinds that have further suppressed risk appetite for capital. Technically, current support is located in the HKD 3.5-3.8 range, which has historically seen rebounds after multiple touches. However, the sustainability of recent rebounds has been average. If there is a short-term increase in volume and the price stabilizes above HKD 4, it may open a window for a rebound and repair the weak pattern. Conversely, if the price breaks support on low volume, there may be a risk of inertia downward movement. Investors are advised to closely monitor the distribution of main funds and the short-term sector atmosphere, and to avoid blindly entering large positions until technical signals are clear. If a rebound stabilizes alongside unusual movements in incremental funds, light participation in short-term opportunities may be considered, with an overall focus on stability and risk control as a priority

Technical Forecast·
HK
01530
-0.17%
HK
01177
+0.79%
Technical Forecast·
HK
01530
-0.17%
HK
01177
+0.79%

Early Morning Trend | LUYE PHARMA retraces to the stage low, can sector linkage change the weakness?

LUYE PHARMA (2186.HK) has recently seen its stock price continue to decline, temporarily retracing to the previous low point area. The daily death cross signal is clear, and the short-term bearish atmosphere dominates the market. From a technical perspective, major indicators such as MACD and RSI are showing weakness, with the 5-day and 10-day moving averages continuing to decline, and the K-line combination leaning towards bearish, indicating ongoing market selling pressure. On the fundamental side, although LUYE PHARMA has launched some new drugs, the industry as a whole has entered a complex phase of stricter policy regulation, price reductions in medical insurance, and high R&D investments, which affects performance improvement in the short term due to various uncertainties. The overall performance of the pharmaceutical sector has seen a recent decline in participation enthusiasm, with major institutions preferring defensive industries or rotating into high-growth areas. In terms of sector linkage, the pharmaceutical sector is weak, with noticeable short-term capital outflows. LUYE PHARMA is constrained by the overall atmosphere, facing systemic adjustment pressure brought about by the industry's "collective bearish" sentiment. In the current sensitive range of the retracement phase, both institutions and short-term funds remain highly sensitive, with price fluctuations easily triggering sector resonance. For future trends, attention should be paid to whether the support at this low point is effective. If strong support is breached, short-term bearish signals may further strengthen; conversely, if funds provide support and lead to a reversal of indicators, there may be a technical rebound in the short term. Investors should strictly control risks, primarily adopting a wait-and-see approach when the bottom is unclear, and if making tentative layouts, set appropriate stop-loss levels

Technical Forecast·
HK
02186
+0.75%
HK
01530
-0.17%
Technical Forecast·
HK
02186
+0.75%
HK
01530
-0.17%

CMB International Securities Reaffirms Their Buy Rating on 3SBio (TRSBF)

CMB International Securities analyst Jill Wu has reaffirmed a Buy rating on 3SBio (TRSBF) with a price target of HK$37.43, while the shares closed at HK$24.26. The analyst has an average return of 39.6% and a success rate of 59.73%. The consensus for 3SBio is a Strong Buy, with a price target consensus of HK$39.95, indicating a potential upside of 64.66%.

Tip Ranks·
SZ
159102
+1.71%
SH
513700
+2.04%
SZ
159316
+1.90%
Tip Ranks·
SZ
159102
+1.71%
SH
513700
+2.04%
SZ
159316
+1.90%

CITIC International expects that the release of the value of 707 drugs will drive 3SBIO upward

The research report from China Merchants Bank International indicates that the drug development program 707/PF'4404, a collaboration between Pfizer and 3SBIO, has progressed beyond expectations, with four global Phase 3 clinical studies expected to start in 2026. This drug is anticipated to become a cornerstone of the next generation of tumor immunotherapy, driving up 3SBIO's stock price. Based on increased competition, the target price has slightly decreased to 37.43 yuan, maintaining a "Buy" rating

AASTOCKS·
SH
520880
+1.00%
SZ
159316
+1.90%
HK
01530
-0.17%
AASTOCKS·
SH
520880
+1.00%
SZ
159316
+1.90%
HK
01530
-0.17%

The Hang Seng Index fell 0.1% at midday, and the Hang Seng TECH Index dropped 0.4%

36Kr learned that the Hang Seng Index fell 0.1% during the midday break, and the Hang Seng TECH Index dropped 0.4%; the non-ferrous metals, pharmaceutical and biotechnology, and software services sectors led the decline, with Hong Kong Exchanges and Clearing falling over 5%, 3SBIO dropping over 4%, and XUNCE falling over 4%; the energy, durable consumer goods, and building materials sectors strengthened, with WISON ENGRG rising over 7%, POP MART and ARTGO HOLDINGS increasing over 1%; southbound funds net bought HKD 3.955 billion

36Kr·
HK
STECH
-1.07%
HK
01530
-0.17%
HK
03313
-2.13%
36Kr·
HK
STECH
-1.07%
HK
01530
-0.17%
HK
03313
-2.13%
Posts
View More
© 2026 Longbridge｜Disclaimer